|Table of Contents|

Expression and clinical significance of FOXA2 and FOXJ2 in serum of HCC patients

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 20
Page:
3817-3821
Research Field:
Publishing date:

Info

Title:
Expression and clinical significance of FOXA2 and FOXJ2 in serum of HCC patients
Author(s):
ZHANG Xin1; RAN Xiaoke1; CHEN Xi1; XU Zongyao1; LI Yanjie1; LI Shanyi1; GAO Qi1; CHEN Xiaoqi2
1The First Clinical School of Medicine,Henan University of Chinese Medicine,Henan Zhengzhou 450000,China;2Department of Spleen,Stomach,Hepatobiliary,the First Affiliated Hospital of Henan University of Chinese Medicine,Henan Zhengzhou 450000,China.
Keywords:
hepatocellular carcinoma; FOXA2; FOXJ2; prognosis
PACS:
R735.7
DOI:
10.3969/j.issn.1672-4992.2023.20.018
Abstract:
Objective:To detect the expression levels of forkhead transcription factors FOXA2 and FOXJ2 in sera of patients with hepatocellular carcinoma (HCC),and to explore the correlation between FOXA2 and FOXJ2 and tumor-related indicators and progression-free survival of HCC patients.Methods:Seventy-two patients with HCC who were admitted to the department of spleen,stomach,hepatobiliary,the First Affiliated Hospital of Henan University of Chinese Medicine from August 2021 to December 2021 were selected and their sera were collected.The expression levels of FOXA2 and FOXJ2 in the sera of HCC patients were detected by enzyme-linked immunoassay,and their correlation with tumor-related indicators and progression-free survival of HCC patients was analyzed.Correlations were analyzed by Spearman test for measurement data and rank data.χ2 test was used for one-way correlation analysis.ROC curve was applied to calculate the area under the curve (AUC) of FOXA2 and FOXJ2,and cut-off values were obtained according to the maximum method of Jorden index.Kaplan-Merier method was used for progression-free survival analysis.Results:Both FOXA2 and FOXJ2 expression levels were correlated with clinical stage of hepatocellular carcinoma (P＜0.05),and the AUC of FOXA2 and FOXJ2 was found to be statistically different for diagnosis by ROC diagnostic curve analysis (P＜0.05),and the cumulative survival rate of HCC patients in the FOXA2 and FOXJ2 high expression group was found to be higher than that of FOXA2 and FOXJ2 patients in the FOXJ2 low expression group by survival curve analysis (P＜0.05).There was a moderately positive correlation between the expression levels of FOXA2 and FOXJ2 in the serum (P＜0.05).Conclusion:The expression levels of FOXA2 and FOXJ2 in the serum of HCC patients are closely related to the development and prognosis of HCC,and can be used as biological markers for judging the disease progression and prognosis of HCC.

References:

［1］ 国家卫生健康委办公厅.原发性肝癌诊疗指南(2022年版)［J］.临床肝胆病杂志,2022,38(02):288-303. General Office of the National Health and Wellness Commission.Guidelines for the management of primary liver cancer (2022 edition) ［J］.Journal of Clinical Hepatobiliary Diseases，2022，38(02):288-303.
［2］ XIA CF,DONG XS,LI H,et al.Cancer statistics in China and United States,2022:profiles,trends,and determinants ［J］.Chin Med J (Engl)，2022，135(5):584-590.
［3］ HAO X,SUN G,ZHANG Y,et al.Targeting immune cells in the tumor microenvironment of HCC:New opportunities and challenges ［J］.Front Cell Dev Biol，2021，9:775462.
［4］ ZHANG XH,GUAN L,TIAN HY,et al.Risk factors and prevention of viral hepatitis-related hepatocellular carcinoma ［J］.Front Oncol，2021，11:686962.
［5］ SUGAWARA Y,HIBI T.Surgical treatment of hepatocellular carcinoma ［J］.Biosci Trends，2021，15(3):138-141.
［6］ DAI YF,QIANG WJ,LIN KQ,et al.An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma ［J］.Cancer Immunol Immunother，2021，70(4):967-979.
［7］ KOCH S.Regulation of Wnt signaling by FOX transcription factors in cancer ［J］.Cancers (Basel)，2021，13(14):3446.
［8］ OREA-SOUFI A,PAIK J,BRAGANCA J,et al.FOXO transcription factors as therapeutic targets in human diseases ［J］.Trends Pharmacol Sci，2022，43(12):1070-1084.
［9］ 冉小柯,陈欣菊,赵云霞,等.叉头转录因子A2、J2在肝细胞癌组织中的表达及意义［J］.临床肝胆病杂志,2021,37(06):1342-1347. RAN SK,CHEN XJ,ZHAO YX,et al.Expression and significance of forkhead transcription factors A2 and J2 in hepatocellular carcinoma tissues ［J］.Journal of Clinical Hepatobiliary Diseases,2021,37(06):1342-1347.
［10］ ANWANWAN D,SINGH SK,SINGH S,et al.Challenges in liver cancer and possible treatment approaches ［J］.Biochim Biophys Acta Rev Cancer,2020,1873(1):188314.
［11］ MAN SL,LUO CL,YAN MY,et al.Treatment for liver cancer:From sorafenib to natural products ［J］.Eur J Med Chem,2021,224:113690.
［12］ XING MT,WANG XZ,KIKEN RA,et al.Immunodiagnostic biomarkers for hepatocellular carcinoma (HCC):The first step in detection and treatment ［J］.Int J Mol Sci,2021,22(11):6139.
［13］ PARK H,PARK H,BAEK J,et al.Target therapy for hepatocellular carcinoma:beyond receptor tyrosine kinase inhibitors and immune checkpoint inhibitors ［J］.Biology (Basel),2022,11(4):585.
［14］ HERMAN L,TODESCHINI AL,VEITIA RA.Forkhead transcription factors in health and disease ［J］.Trends Genet,2021,37(5):460-475.
［15］ JIN Y,LIANG ZQ,LOU HQ.The emerging roles of Fox family transcription factors in chromosome replication,organization,and genome stability ［J］.Cells，2020，9(1):258.
［16］ CASTANEDA M,HOLLANDER PD,MANI SA.Forkhead Box transcription factors:double-edged swords in cancer ［J］.Cancer Res,2022,82(11):2057-2065.
［17］ CAMPBEL SA,STEPHAN TL,LOTTO J,et al.Signalling pathways and transcriptional regulators orchestrating liver development and cancer ［J］.Development，2021，148(17):dev199814.
［18］ DAI SY,QU LZ,LI J,et al.Toward a mechanistic understanding of DNA binding by forkhead transcription factors and its perturbation by pathogenic mutations ［J］.Nucleic Acids Res,2021,49(18):10235-10249.
［19］ LI J,DAI SY,CHEN XJ,et al.Mechanism of forkhead transcription factors binding to a novel palindromic DNA site ［J］.Nucleic Acids Res,2021,49(6):3573-3583.
［20］ GONG Z,YU J,YANG S,et al.FOX transcription factor family in hepatocellular carcinoma ［J］.Biochim Biophys Acta Rev Cancer,2020,1874(1):188376.
［21］ YANG LJ,ZHOU ML,WAMG SL,et al.Long noncoding RNA SAMMSON promotes melanoma progression by inhibiting FOXA2 expression ［J］.Stem Cells Int,2023,2023:8934210.
［22］ GAO HJ,YAN Z,SUN HY,et al.FoXA2 promotes esophageal squamous cell carcinoma progression by ZEB2 activation ［J］.World J Surg Oncol,2021,19(1):286.
［23］ SHEN JY,ZHOU YJ,ZHANG XY,et al.Loss of FoxA2 accelerates neoplastic changes in the intrahepatic bile duct partly via the MAPK signaling pathway ［J］.Aging (Albany NY),2019,11(21):9280-9294.
［24］ SHANG H,SHI LY,JIANG XN,et al.Correlation between high expression of FOXA2 and improved overall survival in ovarian cancer patients ［J］.Med Sci Monit,2021,27:e928763.
［25］ JIN SD,HE J,ZHOU Y,et al.LncRNA FTX activates FOXA2 expression to inhibit non-small-cell lung cancer proliferation and metastasis ［J］.J Cell Mol Med,2020,24(8):4839-4849.
［26］ WANG ZX,SHEN JY,CHEN CW,et al.FOXA2 plays a critical role in hepatocellular carcinoma progression and lenvatinib-associated drug resistance ［J］.Biosci Trends,2023,17(2):136-147.
［27］ HUANG H,WANG YH,HUANG TM,et al.FOXA2 inhibits doxorubicin-induced apoptosis via transcriptionally activating HBP rate-limiting enzyme GFPT1 in HCC cells ［J］.J Physiol Biochem,2021,77(4):625-638.
［28］ CHEN ZJ,XIANG LY,HU ZG,et al.Epigenetically silenced linc00261 contributes to the metastasis of hepatocellular carcinoma via inducing the deficiency of FOXA2 transcription ［J］.Am J Cancer Res,2021,11(1):277-296.
［29］ QIANG Y,FENG L,WANG G,et al.miR-20a/Foxj2 axis mediates growth and metastasis of colorectal cancer cells as identified by integrated analysis ［J］.Med Sci Monit,2020,26:e923559.
［30］ LI Y,ZHU XH,LIU CH,et al.Low FOXJ2 expression is associated with unfavorable postoperative prognosis of patients with epithelial ovarian cancer ［J］.Medicine (Baltimore),2021,100(10):e24759.
［31］ WANG CP,YU YZ,ZHAO H,et al.MicroRNA-454-5p promotes breast cancer progression by inducing epithelial-mesenchymal transition via targeting the FoxJ2/E-cadherin axis ［J］.Oncol Rep,2021,46(1):127.
［32］ ZHANG H,TANG QF,SUN MY,et al.ARHGAP9 suppresses the migration and invasion of hepatocellular carcinoma cells through up-regulating FOXJ2/E-cadherin ［J］.Cell Death Dis,2018,9(9):916.
［33］ ZHANG ZB,MENG GG,WANG L,et al.The prognostic role and reduced expression of FOXJ2 in human hepatocellular carcinoma ［J］.Mol Med Rep,2016,14(1):254-262.

Memo

Memo:
国家科技重大专项（民口）课题（编号：2018ZX10303-502）；河南省科技厅河南省重点研发与推广专项（编号：232102310188）；河南省特色骨干学科中医药第二批学科建设项目（编号：STG-ZYX03-202126）
Last Update: 1900-01-01